Oxford-Emergent licenses Vivalis' EB66 make TB vacc

19 May 2009

The Oxford-Emergent Tuberculosis Consortium, a joint venture between the University of Oxford and Emergent BioSolutions, has signed a commercial  license agreement with US biopharmaceutical firm Vivalis to evaluate  large-scale commercial production capabilities for MVA85A, the  Consortium's new tuberculosis vaccine candidate.

Under the terms of the deal, the Consortium will explore production of  MVA85A using the Vivalis proprietary EB66 cell line, which is derived  from duck embryonic stem cells. This cell line possesses unique  industrial and regulatory characteristics such as long-term genetic  stability and immortality, growth in serum-free medium and  proliferation at high cell densities in suspension, the firms noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight